- Home
- » Tags
- » Tralokinumab
Top View
- Standards, Perspektiven Und Grenzen Der Konservativen Therapie
- A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
- Topical and Systematic Treatment of Atopic Dermatitis to Inform a Clinical Practice Guideline
- Pipeline: Respiratory, Inflammation & Autoimmunity (RIA) Inhaled Therapeutic Leadership; Spearheading Immunology Biologics
- (INN) for Biological and Biotechnological Substances
- Current Perspectives on the Role of Interleukin-1 Signalling in the Pathogenesis of Asthma and COPD
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- RIA TA Strategy 2013
- WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
- 2017 Annual Review & Extract from Annual Report
- Biologics in Pediatric Psoriasis and Atopic Dermatitis: Revolutionizing the Treatment Landscape
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- DERMATOLOGICAL DRUGS UPDATE 2018 Fall Dermatology Update 2018 Montreal, Quebec Thursday, November 15Th 2018
- AZ Enters Licensing Agreements with LEO Pharma
- Tralokinumab Prevents Flares in Moderate-To-Severe Atopic Dermatitis: Post Hoc Analyses of a Randomized Phase 3 Clinical Trial (ECZTRA 3)
- Monoclonal Antibodies in Asthma
- Optumrx Brand Pipeline Forecast
- Tralokinumab in Combination with Topical Corticosteroids for Moderate to Severe Atopic Dermatitis ECZTRA 3 (Eczema Tralokinumab Trial No
- In Adults with Moderate-To-Severe Atopic Dermatitis Inadequately Controlled by Conventional Treatments: a Randomized, Double-Blind, Phase 2A Trial
- Current Perspectives on the Role of Interleukin-1 Signaling in the Pathogenesis of Asthma and COPD
- Treatment of Atopic Dermatitis: What’S New?
- CHMP Agenda of the 25-29 January 2021 Meeting
- CV Blauvelt 1219
- 26Th EADV Congress
- Roskos EBF Talk Sep 2018 FINAL
- Regeneron Pharmaceutical (REGN) Rating OUTPERFORM* [V] Price (27 Feb 14, US$) 338.54 COMMENT Target Price (US$) 340.00¹ 52-Week Price Range 347.62 - 164.80 Market Cap
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
- Report at a Glance: Atopic Dermatitis August 2021
- Antibody News You Should Know July 1 - 15, 2020
- Treatment of Atopic Dermatitis with Biologic Drugs
- Type 2 Inflammation in Atopic Dermatitis and Beyond: Shared Pathophysiology and Clinical Management
- Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
- A Mathematical Model to Identify Optimal Combinations of Drug
- Supporting Information the Therapeutic Antibody Profiler (TAP): Five Computational De- Velopability Guidelines
- New and Emerging Therapies for Alopecia Areata
- A CME/CE-Certified Supplement to Dermatology News
- CV Blauvelt March 2021
- Compounds and Methods for Treating Inflammatory
- Downloaded from Mitochondrial Surface
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Dermatology Dermatology
- Optumrx Drug Pipeline Insights Report
- Adtralza, INN-Tralokinumab